Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations
Status PubMed-not-MEDLINE Language English Country Switzerland Media electronic
Document type Journal Article
Grant support
DKS 2014.11A/B, DKS 2016.24A/B
Deutsche Kinderkrebsstiftung
PubMed
33923026
PubMed Central
PMC8123268
DOI
10.3390/cancers13092075
PII: cancers13092075
Knihovny.cz E-resources
- Keywords
- children and adolescents, refractory and relapsed non-Hodgkin lymphoma, stem cell transplant,
- Publication type
- Journal Article MeSH
Despite poor survival, controversies remain in the treatment for refractory or relapsed pediatric non-Hodgkin lymphoma (r/r NHL). The current project aimed to collect international experience on the re-induction treatment of r/r NHL, hematopoietic stem cell transplantation (HSCT), risk factors associated with outcome, and to suggest treatment recommendations. Inclusion criteria were (i) refractory disease, disease progression or relapse of any NHL subtype except anaplastic large cell lymphoma, (ii) age < 18 years at initial diagnosis, (iii) diagnosis in/after January 2000. Data from 639 eligible patients were evaluable. The eight-year probability of overall survival was 34 ± 2% with highly significant differences according to NHL subtypes: 28 ± 3% for 254 Burkitt lymphoma/leukemia, 50 ± 6% for 98 diffuse large B-cell lymphomas, 57 ± 8% for 41 primary mediastinal large B-cell lymphomas, 27 ± 3% for 177 T-lymphoblastic lymphomas, 52 ± 10% for 34 precursor-B-cell lymphoblastic lymphomas and 30 ± 9% for 35 patients with rare NHL subtypes. Subtype-specific factors associated with survival and treatment recommendations are suggested. There were no survivors without HSCT, except in few very small subgroups. Conclusions: There is an urgent need to further improve survival in r/r NHL. The current study provides the largest real-world series, which underlines the role of HSCT and suggests treatment recommendations.
2nd Department of Pediatrics Semmelweis University 1085 Budapest Hungary
Children's Cancer Centre National Centre for Child Health and Development Tokyo 104 0045 Japan
Department of Pediatric Hematology and Oncology Oslo University Hospital 0424 Oslo Norway
Department of Pediatric Hematology and Oncology University Hospital Valencia 46010 Valencia Spain
Department of Pediatric Oncology Royal Marsden Hospital Surrey SM2 5PT UK
Department of Pediatric Oncology University Children's Hospital Zurich 8032 Zürich Switzerland
Department of Pediatric Oncology University Hospital Le Fe 46026 Valencia Spain
Department of Pediatrics and Adolescent Medicine 2100 Copenhagen Denmark
Hannover Medical School Department of Pediatric Hematology and Oncology 30625 Hannover Germany
Hospices Civils de Lyon Institute of Pediatric Hematology and Oncology 69002 Lyon France
National Research Centre for Pediatric Hematology Oncology and Immunology 129090 Moscow Russia
Pediatric Hematology and Oncology University Medical Centre Hamburg Eppendorf 20246 Hamburg Germany
Princess Máxima Centre for Pediatric Oncology 3584 CS Utrecht The Netherlands
See more in PubMed
Minard-Colin V., Brugieres L., Reiter A., Cairo M.S., Gross T.G., Woessmann W., Burkhardt B., Sandlund J.T., Williams D., Pillon M., et al. Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead. J. Clin. Oncol. 2015;33:2963–2974. doi: 10.1200/JCO.2014.59.5827. PubMed DOI PMC
Reiter A., Schrappe M., Parwaresch R., Henze G., Muller-Weihrich S., Sauter S., Sykora K.W., Ludwig W.D., Gadner H., Riehm H. Non-Hodgkin’s lymphomas of childhood and adolescence: Results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Munster Group. J. Clin. Oncol. 1995;13:359–372. doi: 10.1200/JCO.1995.13.2.359. PubMed DOI
Maramattom L.V., Hari P.N., Burns L.J., Carreras J., Arcese W., Cairo M.S., Costa L.J., Fenske T.S., Lill M., Freytes C.O., et al. Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: A report from the center for international blood and marrow transplant research. Biol. Blood Marrow Transpl. 2013;19:173–179. doi: 10.1016/j.bbmt.2012.11.016. PubMed DOI PMC
Le Deley M.C., Reiter A., Williams D., Delsol G., Oschlies I., McCarthy K., Zimmermann M., Brugieres L. Prognostic factors in childhood anaplastic large cell lymphoma: Results of a large European intergroup study. Blood. 2008;111:1560–1566. doi: 10.1182/blood-2007-07-100958. PubMed DOI
Mitsui T., Mori T., Fujita N., Inada H., Horibe K., Tsurusawa M., Lymphoma Committee J.P.L.L.S.G. Retrospective analysis of relapsed or primary refractory childhood lymphoblastic lymphoma in Japan. Pediatr. Blood Cancer. 2009;52:591–595. doi: 10.1002/pbc.21941. PubMed DOI
Burkhardt B., Reiter A., Landmann E., Lang P., Lassay L., Dickerhoff R., Lakomek M., Henze G., von Stackelberg A. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: A report from the berlin-frankfurt-muenster group. J. Clin. Oncol. 2009;27:3363–3369. doi: 10.1200/JCO.2008.19.3367. PubMed DOI
Landmann E., Burkhardt B., Zimmermann M., Meyer U., Woessmann W., Klapper W., Wrobel G., Rosolen A., Pillon M., Escherich G., et al. Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma. Haematologica. 2017;102:2086–2096. doi: 10.3324/haematol.2015.139162. PubMed DOI PMC
Gross T.G., Hale G.A., He W., Camitta B.M., Sanders J.E., Cairo M.S., Hayashi R.J., Termuhlen A.M., Zhang M.J., Davies S.M., et al. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol. Blood Marrow Transpl. 2010;16:223–230. doi: 10.1016/j.bbmt.2009.09.021. PubMed DOI PMC
Ducassou S., Ferlay C., Bergeron C., Girard S., Laureys G., Pacquement H., Plantaz D., Lutz P., Vannier J.P., Uyttebroeck A., et al. Clinical presentation, evolution, and prognosis of precursor B-cell lymphoblastic lymphoma in trials LMT96, EORTC 58881, and EORTC 58951. Br. J. Haematol. 2011;152:441–451. doi: 10.1111/j.1365-2141.2010.08541.x. PubMed DOI
Michaux K., Bergeron C., Gandemer V., Mechinaud F., Uyttebroeck A., Bertrand Y., SFCE. The EORTC Children Leukemia Group Relapsed or Refractory Lymphoblastic Lymphoma in Children: Results and Analysis of 23 Patients in the EORTC 58951 and the LMT96 Protocols. Pediatr. Blood Cancer. 2016;63:1214–1221. doi: 10.1002/pbc.25990. PubMed DOI
Mitsui T., Fujita N., Koga Y., Fukano R., Osumi T., Hama A., Koh K., Kakuda H., Inoue M., Fukuda T., et al. The effect of graft-versus-host disease on outcomes after allogeneic stem cell transplantation for refractory lymphoblastic lymphoma in children and young adults. Pediatr. Blood Cancer. 2020;67:e28129. doi: 10.1002/pbc.28129. PubMed DOI
Cairo M.S., Gerrard M., Sposto R., Auperin A., Pinkerton C.R., Michon J., Weston C., Perkins S.L., Raphael M., McCarthy K., et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2007;109:2736–2743. doi: 10.1182/blood-2006-07-036665. PubMed DOI PMC
Patte C., Auperin A., Gerrard M., Michon J., Pinkerton R., Sposto R., Weston C., Raphael M., Perkins S.L., McCarthy K., et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: It is possible to reduce treatment for the early responding patients. Blood. 2007;109:2773–2780. doi: 10.1182/blood-2006-07-036673. PubMed DOI PMC
Gerrard M., Cairo M.S., Weston C., Auperin A., Pinkerton R., Lambilliote A., Sposto R., McCarthy K., Lacombe M.J., Perkins S.L., et al. Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin’s lymphoma: Results of the FAB/LMB 96 international study. Br. J. Haematol. 2008;141:840–847. doi: 10.1111/j.1365-2141.2008.07144.x. PubMed DOI
Woessmann W., Seidemann K., Mann G., Zimmermann M., Burkhardt B., Oschlies I., Ludwig W.D., Klingebiel T., Graf N., Gruhn B., et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: A report of the BFM Group Study NHL-BFM95. Blood. 2005;105:948–958. doi: 10.1182/blood-2004-03-0973. PubMed DOI
Pillon M., Di Tullio M.T., Garaventa A., Cesaro S., Putti M.C., Favre C., Lippi A., Surico G., Di Cataldo A., D’Amore E., et al. Long-term results of the first Italian Association of Pediatric Hematology and Oncology protocol for the treatment of pediatric B-cell non-Hodgkin lymphoma (AIEOP LNH92) Cancer. 2004;101:385–394. doi: 10.1002/cncr.20382. PubMed DOI
Pillon M., Mussolin L., Carraro E., Conter V., Arico M., Vinti L., Garaventa A., Piglione M., Buffardi S., Sala A., et al. Detection of prognostic factors in children and adolescents with Burkitt and Diffuse Large B-Cell Lymphoma treated with the AIEOP LNH-97 protocol. Br. J. Haematol. 2016;175:467–475. doi: 10.1111/bjh.14240. PubMed DOI
Osumi T., Mori T., Fujita N., Saito A.M., Nakazawa A., Tsurusawa M., Kobayashi R. Relapsed/refractory pediatric B-cell non-Hodgkin lymphoma treated with rituximab combination therapy: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group. Pediatr. Blood Cancer. 2016;63:1794–1799. doi: 10.1002/pbc.26105. PubMed DOI
Rigaud C., Auperin A., Jourdain A., Haouy S., Couec M.L., Aladjidi N., Gandemer V., Lambliotte A., Plat G., Landman-Parker J., et al. Outcome of relapse in children and adolescents with B-cell non-Hodgkin lymphoma and mature acute leukemia: A report from the French LMB study. Pediatr. Blood Cancer. 2019;66:e27873. doi: 10.1002/pbc.27873. PubMed DOI
Woessmann W., Zimmermann M., Meinhardt A., Müller S., Hauch H., Knörr F., Oschlies I., Klapper W., Niggli F., Kabickova E., et al. Progressive or relapsed Burkitt lymphoma or leukemia in children and adolescents after BFM-type first-line therapy. Blood. 2020;135:1124–1132. doi: 10.1182/blood.2019003591. PubMed DOI
Fujita N., Kobayashi R., Atsuta Y., Iwasaki F., Suzumiya J., Sasahara Y., Inoue M., Koh K., Hori T., Goto H., et al. Hematopoietic stem cell transplantation in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma. Int. J. Hematol. 2019;109:483–490. doi: 10.1007/s12185-019-02608-y. PubMed DOI
Jourdain A., Auperin A., Minard-Colin V., Aladjidi N., Zsiros J., Coze C., Gandemer V., Bertrand Y., Leverger G., Bergeron C., et al. Outcome of and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective “Lymphomes Malins B” protocols. A Societe Francaise des Cancers de l’Enfant study. Haematologica. 2015;100:810–817. doi: 10.3324/haematol.2014.121434. PubMed DOI PMC
Cairo M., Auperin A., Perkins S.L., Pinkerton R., Harrison L., Goldman S., Patte C. Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: A report from the FAB/LMB 96 study group. Br. J. Haematol. 2018;182:859–869. doi: 10.1111/bjh.15491. PubMed DOI PMC
Anoop P., Sankpal S., Stiller C., Tewari S., Lancaster D.L., Khabra K., Taj M.M. Outcome of childhood relapsed or refractory mature B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia. Leuk. Lymphoma. 2012;53:1882–1888. doi: 10.3109/10428194.2012.677534. PubMed DOI
Kim H., Park E.S., Lee S.H., Koo H.H., Kim H.S., Lyu C.J., Jun S.E., Lim Y.T., Baek H.J., Kook H., et al. Clinical outcome of relapsed or refractory burkitt lymphoma and mature B-cell lymphoblastic leukemia in children and adolescents. Cancer Res. Treat. 2014;46:358–365. doi: 10.4143/crt.2013.047. PubMed DOI PMC
Minard-Colin V., Auperin A., Pillon M., Burke G.A.A., Barkauskas D.A., Wheatley K., Delgado R.F., Alexander S., Uyttebroeck A., Bollard C.M., et al. Rituximab for High-Risk, Mature B-Cell Non-Hodgkin’s Lymphoma in Children. N. Engl. J. Med. 2020;382:2207–2219. doi: 10.1056/NEJMoa1915315. PubMed DOI PMC
Mellgren K., Attarbaschi A., Abla O., Alexander S., Bomken S., Bubanska E., Chiang A., Csoka M., Fedorova A., Kabickova E., et al. Non-anaplastic peripheral T cell lymphoma in children and adolescents-an international review of 143 cases. Ann. Hematol. 2016;95:1295–1305. doi: 10.1007/s00277-016-2722-y. PubMed DOI
Kontny U., Oschlies I., Woessmann W., Burkhardt B., Lisfeld J., Salzburg J., Janda A., Attarbaschi A., Niggli F., Zimmermann M., et al. Non-anaplastic peripheral T-cell lymphoma in children and adolescents--a retrospective analysis of the NHL-BFM study group. Br. J. Haematol. 2015;168:835–844. doi: 10.1111/bjh.13216. PubMed DOI
Gerrard M., Waxman I.M., Sposto R., Auperin A., Perkins S.L., Goldman S., Harrison L., Pinkerton R., McCarthy K., Raphael M., et al. Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy. Blood. 2013;121:278–285. doi: 10.1182/blood-2012-04-422709. PubMed DOI PMC
Woessmann W., Lisfeld J., Burkhardt B., Group N.-B.S. Therapy in primary mediastinal B-cell lymphoma. N. Engl. J. Med. 2013;369:282. doi: 10.1056/NEJMc1305983#SA1. PubMed DOI
Pillon M., Carraro E., Mussolin L., Conter V., Tondo A., Arico M., Mura R., Sala A., Vinti L., Buffardi S., et al. Primary mediastinal large B-cell lymphoma: Outcome of a series of pediatric patients treated with high-dose methotrexate and cytarabine plus anti-CD20. Pediatr. Blood Cancer. 2018;65 doi: 10.1002/pbc.26855. PubMed DOI
Griffin T.C., Weitzman S., Weinstein H., Chang M., Cairo M., Hutchison R., Shiramizu B., Wiley J., Woods D., Barnich M., et al. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: A report from the Children’s Oncology Group. Pediatr. Blood Cancer. 2009;52:177–181. doi: 10.1002/pbc.21753. PubMed DOI PMC
Burke G.A.A., Beishuizen A., Bhojwani D., Burkhardt B., Minard-Colin V., Norris R.E., Kabickova E., Pinarli F.G., Tacyildiz N., Howes A., et al. Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): Initial safety, pharmacokinetics, and efficacy. Leukemia. 2020;34:2271–2275. doi: 10.1038/s41375-020-0749-5. PubMed DOI PMC
Reiter A., Klapper W. Recent advances in the understanding and management of diffuse large B-cell lymphoma in children. Br. J. Haematol. 2008;142:329–347. doi: 10.1111/j.1365-2141.2008.06988.x. PubMed DOI
Pearson A.D.J., Scobie N., Norga K., Ligas F., Chiodin D., Burke A., Minard-Colin V., Adamson P., Marshall L.V., Balakumaran A., et al. ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children. Eur. J. Cancer. 2019;110:74–85. doi: 10.1016/j.ejca.2019.01.013. PubMed DOI
Kobayashi R., Takimoto T., Nakazawa A., Fujita N., Akazai A., Yamato K., Yazaki M., Deguchi T., Hashii Y., Kato K., et al. Inferior outcomes of stage III T lymphoblastic lymphoma relative to stage IV lymphoma and T-acute lymphoblastic leukemia: Long-term comparison of outcomes in the JACLS NHL T-98 and ALL T-97 protocols. Int. J. Hematol. 2014;99:743–749. doi: 10.1007/s12185-014-1585-z. PubMed DOI
Willasch A.M., Peters C., Sedlacek P., Dalle J.H., Kitra-Roussou V., Yesilipek A., Wachowiak J., Lankester A., Prete A., Hamidieh A.A., et al. Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?-A multicenter EBMT-PDWP study. Bone Marrow Transpl. 2020;55:1540–1551. doi: 10.1038/s41409-020-0854-0. PubMed DOI PMC
Peters C., Dalle J.H., Locatelli F., Poetschger U., Sedlacek P., Buechner J., Shaw P.J., Staciuk R., Ifversen M., Pichler H., et al. Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study. J. Clin. Oncol. 2020 doi: 10.1200/JCO.20.02529. PubMed DOI PMC
Levine J.E., Harris R.E., Loberiza F.R., Jr., Armitage J.O., Vose J.M., Van Besien K., Lazarus H.M., Horowitz M.M., Bashey A., Bolwell B.J., et al. A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood. 2003;101:2476–2482. doi: 10.1182/blood-2002-05-1483. PubMed DOI
Reiter A., Schrappe M., Tiemann M., Ludwig W.D., Yakisan E., Zimmermann M., Mann G., Chott A., Ebell W., Klingebiel T., et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood. 1999;94:3294–3306. PubMed
Grigg A., Ritchie D. Graft-versus-lymphoma effects: Clinical review, policy proposals, and immunobiology. Biol. Blood Marrow Transpl. 2004;10:579–590. doi: 10.1016/j.bbmt.2004.05.008. PubMed DOI
Petersen S.L. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Dan Med. Bull. 2007;54:112–139. PubMed
Schmitz N., Dreger P., Glass B., Sureda A. Allogeneic transplantation in lymphoma: Current status. Haematologica. 2007;92:1533–1548. doi: 10.3324/haematol.11185. PubMed DOI
Giulino-Roth L., Ricafort R., Kernan N.A., Small T.N., Trippett T.M., Steinherz P.G., Prockop S.E., Scaradavou A., Chiu M., O’Reilly R.J., et al. Ten-year follow-up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation. Pediatr. Blood Cancer. 2013;60:2018–2024. doi: 10.1002/pbc.24722. PubMed DOI
Okur F.V., Krance R. Stem cell transplantation in childhood non-Hodgkin’s lymphomas. Curr. Hematol. Malig. Rep. 2010;5:192–199. doi: 10.1007/s11899-010-0059-5. PubMed DOI
Aukema S.M., Theil L., Rohde M., Bauer B., Bradtke J., Burkhardt B., Bonn B.R., Claviez A., Gattenlohner S., Makarova O., et al. Sequential karyotyping in Burkitt lymphoma reveals a linear clonal evolution with increase in karyotype complexity and a high frequency of recurrent secondary aberrations. Br. J. Haematol. 2015;170:814–825. doi: 10.1111/bjh.13501. PubMed DOI
Mussolin L., Pillon M., d’Amore E.S., Conter V., Piglione M., Lo Nigro L., Garaventa A., Buffardi S., Arico M., Rosolen A. Minimal disseminated disease in high-risk Burkitt’s lymphoma identifies patients with different prognosis. J. Clin. Oncol. 2011;29:1779–1784. doi: 10.1200/JCO.2010.32.8161. PubMed DOI
Richter J., Schlesner M., Hoffmann S., Kreuz M., Leich E., Burkhardt B., Rosolowski M., Ammerpohl O., Wagener R., Bernhart S.H., et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat. Genet. 2012;44:1316–1320. doi: 10.1038/ng.2469. PubMed DOI
Callens C., Baleydier F., Lengline E., Ben Abdelali R., Petit A., Villarese P., Cieslak A., Minard-Colin V., Rullier A., Moreau A., et al. Clinical impact of NOTCH1 and/or FBXW7 mutations, FLASH deletion, and TCR status in pediatric T-cell lymphoblastic lymphoma. J. Clin. Oncol. 2012;30:1966–1973. doi: 10.1200/JCO.2011.39.7661. PubMed DOI
Bonn B.R., Rohde M., Zimmermann M., Krieger D., Oschlies I., Niggli F., Wrobel G., Attarbaschi A., Escherich G., Klapper W., et al. Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence. Blood. 2013;121:3153–3160. doi: 10.1182/blood-2012-12-474148. PubMed DOI
Balbach S.T., Makarova O., Bonn B.R., Zimmermann M., Rohde M., Oschlies I., Klapper W., Rossig C., Burkhardt B. Proposal of a genetic classifier for risk group stratification in pediatric T-cell lymphoblastic lymphoma reveals differences from adult T-cell lymphoblastic leukemia. Leukemia. 2016;30:970–973. doi: 10.1038/leu.2015.203. PubMed DOI
Lopez C., Kleinheinz K., Aukema S.M., Rohde M., Bernhart S.H., Hubschmann D., Wagener R., Toprak U.H., Raimondi F., Kreuz M., et al. Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma. Nat. Commun. 2019;10:1459. doi: 10.1038/s41467-019-08578-3. PubMed DOI PMC
Reutter K., Sandmann S., Rohde J., Müller S., Wöste M., Khanam T., Michgehl U., Klapper W., Wößmann W., Seggewiß J., et al. Reconstructing clonal evolution in relapsed and non-relapsed Burkitt lymphoma. Leukemia. 2020 doi: 10.1038/s41375-020-0862-5. PubMed DOI PMC
Khanam T., Sandmann S., Seggewiss J., Ruether C.M., Zimmermann M., Norvil A.B., Bartenhagen C., Randau G., Mueller S., Herbrüggen H., et al. Integrative genomic analysis of pediatric T- cell lymphoblastic lymphoma reveals candidates of clinical significance. Blood. 2020 doi: 10.1182/blood.2020005381. PubMed DOI PMC
Pomari E., Lovisa F., Carraro E., Primerano S., D’Amore E.S.G., Bonvini P., Nigro L.L., Vito R., Vinti L., Farruggia P., et al. Clinical impact of miR-223 expression in pediatric T-Cell lymphoblastic lymphoma. Oncotarget. 2017;8:107886–107898. doi: 10.18632/oncotarget.22386. PubMed DOI PMC
